Navigation Links
Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
Date:12/21/2010

agent for the initial signing of the facility and will receive a fee for its services at the time of any draw under the facility.

In connection with the execution of the equity financing facility, Poniard will issue to Small Cap Biotech 221,218 shares of registered common stock as a commitment fee.  The offer and sale of shares by Poniard under the equity facility have been registered pursuant to a shelf registration statement declared effective with the Securities and Exchange Commission on June 2, 2009.  Poniard intends to use the net proceeds from any sale of shares under the facility for working capital and other general corporate purposes.

"Repayment of our secured credit facility removes significant restrictions on our cash and assets and gives Poniard additional flexibility for the completion of our review of strategic alternatives," said Ronald A. Martell, chief executive officer of Poniard Pharmaceuticals.  "The new equity financing facility provides us with access to additional working capital to support our operations, while allowing for control over timing and dilution."

Immediately prior to entering into the new equity financing facility with Small Cap Biotech, the Company and Commerce Court Small Cap Value Fund, Ltd., by mutual agreement, terminated the equity financing facility between the Company and Commerce Court dated February 23, 2010.  The Company completed a drawdown of 4,229,000 shares of its common stock under the Commerce Court facility on March 15, 2010, for which the Company received net proceeds of approximately $6.1 million.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Poniard Pharmaceuticals

P
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
2. Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
3. Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program
4. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
5. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
6. Poniard Pharmaceuticals Announces $6.3 Million Financing
7. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
8. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
9. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
10. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
11. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... H. Burbank , Chief Executive Officer, and Mathew Towse ... Annual Canaccord Genuity Growth Conference being held at the ... August 13 th at 4:30 p.m. ET.  A webcast ... .  About NxStage Medical NxStage ...
(Date:8/1/2014)... , Aug. 1, 2014 Inovio Pharmaceuticals, Inc. ... a conference call to report its second quarter 2014 ... AM ET. CEO Dr. J. Joseph Kim ... quarter earnings, provide a corporate update, and participate in ... clinical development plans for VGX-3100, Inovio,s immune therapy targeting ...
(Date:8/1/2014)... , Aug. 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds ... Potassium Nitrate Industry" and "2014 Deep Research Report ... reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5
... 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. ... an emerging leader in the development, assembly, marketing and ... announced that the Company will present at the CFA ... the Shanghai Purple Mountain Hotel in Shanghai on May ...
... May 17, 2012 Simbionix USA ... training and education products, is proud to announce ... the new GI Mentor™ Express simulator ... Mentor™ .      (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a) ...
Cached Medicine Technology:Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai 2Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events 2
(Date:8/1/2014)... (PRWEB) August 01, 2014 The European gas ... Europe with analysis and forecast of revenue. The gas chromatography ... 2013, and is estimated to grow to around $247.6 million ... 2018. , Browse through the TOC of the European gas ... analysis provided. This also provides a glimpse of the segmentation ...
(Date:8/1/2014)... August 01, 2014 Recently, Agebc.com, a renowned ... of prom dresses . As a matter of fact, ... top experts. Aside from that, all of them are offered ... has a huge selection of graceful products for clients who ... sale will not last for a long period of time. ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted to ... Curran, PhD, of the University of Southern California as ... Award. , This distinguished honor is given for outstanding ... research. It was established in 1986 to honor Nathan ... in gerontological research at the National Institutes of Health. ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new ... clients who have high cholesterol levels. , Clients ... qualify for no medical exam life insurance. These plans ... medical check-ups. , Since there are no medical examinations ... qualify in just a few minutes. However, this convenience ...
(Date:8/1/2014)... 01, 2014 Frontier Nursing University has ... Services Administration’s Advanced Education Nursing Traineeship (AENT) program ... direct support to 280 students over the grant period. ... is to increase the number of advanced education nurses ... faculty to address the nurse faculty shortage that inhibits ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cheap Prom Dresses At The Renowned Dresses Manufacturer and Retailer Agebc.com 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2
... a new, targeted therapy for metastatic urothelial cancer has ... 35th Congress of the European Society for Medical Oncology ... tissue lining the inner surfaces of the bladder and ... metastatic disease, median survival is approximately 12-15 months and ...
... diagnosed with bone cancer could benefit from better treatment in ... Nottingham. The Bone Cancer Research Trust launches Bone Cancer ... the University which is testing a theory that ,friendly bacteria, ... at the School of Clinical Sciences, Division of Pre-Clinical Oncology ...
... cardiovascular surgeons and cardiologists from 25 countries are scheduled ... two-day surgical congress focused on the Ross Procedure. ... will feature the presentation of much new data about ... the world,s elite cardiovascular surgeons and cardiologists regarding survival, ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... be at higher risk for stroke even if they don,t ... attention to people who show signs of insulin resistance -- ... clear glucose from the bloodstream -- may be helpful in ...
... cancer can lead some people to wonder if their risk ... than 85,000 postmenopausal women observed that regular physical activity, maintaining ... risk for women with, and without a family history of ... published online Oct. 12, 2010, by the journal Breast ...
... artery that supplies blood to the brain, carotid artery ... an increased risk of both short- and long-term adverse ... to a meta-analysis of previously published studies that was ... 2011 print issue of Archives of Neurology , ...
Cached Medicine News:Health News:Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer 2Health News:Hope for a new treatment for bone cancer 2Health News:The Ross Summit to focus on new survival data, technique refinement and availability 2Health News:Insulin Resistance Might Raise Risk of Stroke 2Health News:Insulin Resistance Might Raise Risk of Stroke 3Health News:Breast-healthy lifestyle worthwhile, URMC study confirms 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: